Sample Report

U.S. Oncology Genomics Tracker - Wave 1, Q2 2025

The focus of the U.S. Oncology Genomics Tracker is to characterize the current clinical use of genomic testing across clinical applications (e.g., genomic profiling, MRD / recurrence monitoring, treatment response monitoring) and track how use changes over time. Respondents were asked about use of genomic testing within routine clinical practice within the past 3 months.

The survey was distributed randomly to U.S. oncologists. Respondents were selected to complete the survey if they were an actively-practicing board-certified medical oncologist or hematologist-oncologist, U.S.-based and had seen at least 40 patients over the past 3 months. Respondents were not screened out of the survey if they were not currently using, or had not previously used, genomics for biomarker testing.

See more details below.

 

 

Complete this form to receive a copy of the sample report.

Survey Scope:

68713d501993e295d64dddda_Screenshot 2025-07-11 at 12.35.00 PM

Respondent demographics from Wave 1 (Q2 2025) of the Oncology Genomics Tracker.

 
Survey Scope & Design:
  • Structured as a recall-based survey
  • For most questions, respondents were directed to answer in the context of patients treated and/or experiences within the past 3 months
  • Respondents were directed to answer in the context of patients treated in routine clinical care and not in the context of clinical trials
  • For MRD and monitoring, respondents were directed to answer in the context of solid-tumor testing
  • Logic was used to display certain questions to respondents based on prior responses (e.g., familiarity, testing rates, etc.) – thus, not all respondents answered all questions (i.e.,respondents were not shown questions that were irrelevant to them based on their practices)
  • The median duration of completion was 24 minutes
 
Survey Limitations / Considerations:
  • Survey format: This is a recall-based survey, which relies on oncologists’ ability to recall specific information, which is imperfect
  • Survey N: Given the number of medical oncologists / oncologist-hematologists in theU.S. (13,400), the 100 survey responses captured here represent a margin of error of 9-10% at a 95% confidence interval
  • Stakeholder type: Oncologists are the primary stakeholder for deciding to order tests, but mayor may not be involved in actually executing the order (a nurse and / or pathologist can often play that role), thus the oncologist may not be entirely familiar with the details of the tests ordered (e.g., which types of tests from which labs)
  • Definitions: Oncologist’s may have definitions that differ from those used / described in this survey and may have answered questions according to their personal definitions (e.g., some respondents included lymphomas in their definition of solid tumors, while others did not)
  • Selection bias: Oncologists that actively and regularly order biomarker testing are more likely to take a survey related to oncology biomarker testing, potentially overrepresenting adoption and utilization figures, especially for emerging methods‍
  • Adherence to directions: Oncologists were directed to answer the questions within a specific context(e.g., solid-tumor patients treated within routine care (i.e., not trials) within the past 3 months) – it is possible that oncologists deviated from these guardrails when responding to questions
  • Respondent mix: The mix of respondents by setting for this survey (52% community-based, 48%AMC-based) is not mapped to the overall distribution of oncology care in theU.S. (which is closer to ~85% community-based, 15% AMC-based)
  • Volume vs. market share: Any share figures here correspond to volume share and are not necessarily reflective of market share
  • Early access users: Some clinicians / institutions participate in early-access programs which give them access to tests prior to public / commercial launch of an assay, which could be captured here